This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BioTelemetry, Inc. Announces Newly Published Research Demonstrating Significant Cost Savings With Use Of Mobile Cardiac Telemetry

Stocks in this article: BEAT

MALVERN, Pa., Dec. 12, 2013 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that recently published research from an observational study of more than 200,000 patients demonstrates significant in-hospital cost savings in the twelve months following diagnosis using mobile cardiac telemetry ("MCT").

A retrospective analysis was completed on claims data spanning 57 months and more than 200,000 patients to compare diagnostic efficacy, therapeutic outcomes and cardiovascular costs incurred in the hospital setting for patients diagnosed with MCT, Holter and event devices. Results published in Medical Device: Evidence and Research demonstrate a significantly higher diagnostic yield in patients utilizing MCT, at 61%, compared to event, at 23%, and Holter, at 24%.  Therapeutic intervention measured through the prescription of antiarrhythmic drugs was also substantially higher in patients monitored with MCT, at 61%, compared to event, at 39%, and Holter, at 43%. The study's most significant finding was the level of cost savings per patient in cardiovascular in-hospital costs when an MCT is used versus either an event or Holter monitor. The study shows that the substitution of the MCT for an event or Holter monitor provides a 10 to 15 times return on investment in the first 12 months post-utilization. 

Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, commented: "With the shift in healthcare payments from procedure-based to outcomes-based, we are pleased, but not surprised, with the results of this large scale study. While the diagnostic superiority of our MCOT technology has been demonstrated repeatedly through numerous peer-reviewed studies and abstracts, these prior studies have stopped short of evaluating the actual cost-benefit of MCOT use resulting from the improved efficacy and better outcomes. This data provides evidence that MCOT is a cost beneficial technology that delivers unsurpassed results to physicians while also reducing overall healthcare spending. This is one of the few studies to validate real savings derived from the application of a mobile health platform. We look forward to sharing this newly released data with our healthcare partners."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs